638 Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's DiseaseBrian Bressler, Gerassimos J. Mantzaris, Neil R. Brett et al.|The American Journal of Gastroenterology|2019Cited by 6
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVEGerassimos J. Mantzaris, Andrés Yarur, Brian Bressler et al.|Journal of Crohn s and Colitis|2020Cited by 4